Ágnes Szilágyi

Dr. Ágnes Szilágyi

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Clinical and Translational Allergy
Verified
Journal Article
Open access
MIMarius‐Ionuţ Iuraşcu
Marius‐Ionuţ Iuraşcu
ZBZsuzsanna Balla
Zsuzsanna Balla
CPCatarina Pereira
Catarina Pereira
NANoémi Andrási
Noémi Andrási
LVLilian Varga
Lilian Varga
HFHenriette Farkas
Henriette Farkas
Background: Hereditary angioedema (HAE) with C1‐inhibitor deficiency (C1‐INH‐HAE) is a rare disease caused by low level (type I) or dysfunction (type II) of the C1‐inhibitor protein with subsequent reduction of certain complement protein levels.Methods: To develop and test the reliability of a two‐tier method based on C1‐INH and C4 quantitation followed by genetic analysis from dried blood spot (DBS) for establishing the diagnosis of C1‐INH‐HAE. C1‐INH and C4 proteins have been quantified in human plasma using a classical immuno‐assay and in DBS using a newly developed proteolytic liquid chromatography–mass spectrometry method. Genetic analysis was carried out as reported previously (PMID: 35386643) and by a targeted next‐generation sequencing panel, multiplex ligation‐dependent probe amplification and in some cases whole genome sequencing.Results: DBS quantification of C1‐INH and C4 showed the same pattern as plasma, offering the possibility of screening patients with AE symptoms either locally or remotely. Genetic analysis from DBS verified each of the previously identified SERPING1 mutations of the tested C1‐INH‐HAE patients and revealed the presence of other rare variations in genes that may be involved in the pathogenesis of AE episodes.Conclusions: C1‐INH/C4 quantification in DBS can be used for screening of hereditary AE and DNA extracted from dried blood spots is suitable for identifying various types of mutations of the SERPING1 gene.

11 September 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MDMárton Doleschall
Márton Doleschall
JSJulianna Anna Szabó
Julianna Anna Szabó
JPJúlia Pázmándi
Júlia Pázmándi
ÁSÁgnes Szilágyi
Ágnes Szilágyi
KKKlára Koncz
Klára Koncz
APAttila Patocs
Attila Patocs
Systematic evaluation of the potential relationship between the common genetic variants of CYP21A2 and hormone levels. The relationships of CYP21A2 intron 2 polymorphisms and haplotypes with diverse baseline and stimulated blood hormone levels were studied in 106 subjects with non-functioning adrenal incidentaloma (NFAI). The rationale for using NFAI subjects is dual: i) their baseline hormone profiles do not differ from those of healthy subjects and ii) hormone levels after stimulation tests are available. The carriers (N = 27) of a well-defined CYP21A2 haplotype cluster (c5) had significantly elevated levels of cortisol (p = 0.0110), and 17-hydroxyprogesterone (p = 0.0001) after ACTH stimulation, and 11-deoxycortisol after metyrapone administration (p = 0.0017), but the hormone values were in normal ranges. In addition, the carriers (N = 33) of the C allele of the rs6462 polymorphism had a higher baseline aldosterone level (p = 0.0006). The prevalence of these genetic variants of CYP21A2 did not differ between NFAI and healthy subjects. The common CYP21A2 variants presumably exert the same effect on hormone levels in the healthy and disease-affected populations. Therefore, they may contribute to complex diseases such as some cardiovascular diseases, and may influence the genotype-phenotype correlation in patients with congenital adrenal hyperplasia (CAH) including the individual need for hormone substitution.

28 July 2021 in Genes
Verified
Journal Article
Open access
PDF file
ZPZoltán Pozsonyi
Zoltán Pozsonyi
GPGergely Peskó
Gergely Peskó
HTHedvig Takács
Hedvig Takács
DCDorottya Csuka
Dorottya Csuka
VNViktória Nagy
Viktória Nagy
Róbert SeppRóbert Sepp
Róbert Sepp
Background: Variant transthyretin amyloidosis (ATTRv) is an autosomal dominant inherited disease, where the mutation of the transthyretin gene (TTR) results in the deposition of pathogenic protein fibrils in various tissues. The mutation type influences the clinical course. Until now, no data were available on the genotype, phenotype, and prevalence of Hungarian ATTRv patients. The aim of our study was to assess the prevalence, regional distribution, genotypes, and phenotypes of Hungarian patients with ATTRv. Methods: With the collaboration of Hungarian regional and university centers, we identified patients diagnosed with ATTRv. We also searched prior publications for case studies of Hungarian ATTRv patients. Results: 40 individuals in 23 families with ATTRv were identified within the borders of Hungary. At the time of the diagnosis, 24 of them were symptomatic. The two most common mutations were ATTRHis88Arg (nine families) and ATTRIle107Val (8 families). ATTRVal30Met was demonstrated in 2 families, and ATTRVal122del, ATTRPhe33Leu, ATTRIle84Ser, and ATTRAsp18Gly in one family each. The median age of the symptomatic patients at the time of clinical diagnosis was 65 years. The most common clinically significant organ involvement was restrictive cardiomyopathy, found in 24 patients. Polyneuropathy was diagnosed in 20 patients. A total of 19 patients showed a mixed phenotype. The leading symptom was heart failure in 8 cases (3 of them had only cardiac symptoms), polyneuropathy in 11 cases (all of them also had cardiac symptoms), and equally severe cardiac and neuropathy symptoms were present in 3 cases. Out of 24 symptomatic patients, 10 received targeted pharmacological therapy. The follow-up period ranged from 1 to 195 months. At the time of the retrospective analysis, 12 patients had already died, and 1 patient underwent heart transplantation. Conclusions: As TTR genotype influences the phenotype and clinical course of ATTRv, it is important to know the regional data. In Hungary, ATTRHis88Arg and ATTRIle107Val are the most common mutations in ATTRv, both presenting with mixed phenotype, but the median age at the time of the diagnosis is 9 years lower in patients with ATTRHis88Arg than in patients with ATTRIle107Val.

24 February 2009 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
KHKristof Hirschberg
Kristof Hirschberg
TGTímea Gombos
Tímea Gombos
EDEdit Dósa
Edit Dósa
ASAttila Somorjai
Attila Somorjai
ÁSÁgnes Szilágyi
Ágnes Szilágyi
LELászló Entz
László Entz

20 December 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ALAndrea Lehoczki
Andrea Lehoczki
ÁKÁgnes Király
Ágnes Király
AVAndrea Várkonyi
Andrea Várkonyi
STSzabolcs Tasnády
Szabolcs Tasnády
HAHajnalka Andrikovics
Hajnalka Andrikovics
Gabor MikalaGabor Mikala
Gabor Mikala
Background: Thrombotic microangiopathy (TMA) is a potentially life-threatening complication associated with carfilzomib, a proteasome inhibitor approved for treating multiple myeloma. TMA typically presents within the initial months of treatment; however, delayed onset is rare and poses significant diagnostic challenges. Methods: We conducted a retrospective analysis of the medical records of a 47-year-old Caucasian woman diagnosed with IgA kappa myeloma who developed signs and symptoms consistent with TMA eleven months after the initiation of carfilzomib therapy and already in ongoing very good partial remission. Results: The clinical presentation included an acute onset of weakness, dizziness, somnolence, diffuse bruising, oliguria, jaundice, severe thrombocytopenia, and acute kidney injury. An immediate workup raised a strong suspicion for TMA, confirmed by laboratory findings of schistocytosis and complement activation. Following the immediate discontinuation of carfilzomib, the patient underwent 18 plasmapheresis (PEX) sessions and received supportive fresh frozen plasma transfusions, which resulted in the complete remission of TMA symptoms without the need for complement inhibitory therapy. Conclusions: The need for ongoing monitoring for TMA throughout carfilzomib therapy, regardless of treatment duration, is emphasized. Early diagnosis and intervention, including drug discontinuation and the timely initiation of PEX, are crucial for patient recovery.

22 April 2026 in Kidney International Reports
Verified
Journal Article
Open access
SNSimon Péter Nagy
Simon Péter Nagy
SDSarolta Dobner
Sarolta Dobner
FSFanni Szumutku
Fanni Szumutku
ASAlice Schmidt
Alice Schmidt
GSGere Sunder-Plassmann
Gere Sunder-Plassmann
ÁSÁgnes Szilágyi
Ágnes Szilágyi
The role of noncanonical intronic splice site variants in atypical hemolytic uremic syndrome (aHUS) cases without identified pathogenic variants has long been postulated. We previously identified a novel intronic variant (c.328+42G>A) in the complement factor I (CFI) gene in a patient with factor I (FI) deficiency. This study aimed to identify additional carriers and functionally characterize this variant and its impact on the expression of FI, a crucial complement regulator with a well-established role in aHUS. After screening our genetic registry for patients with potential FI-driven pathologies, the identified c.328+42G>A carriers and their family members underwent comprehensive complement profiling and genetic analysis. To investigate mRNA isoforms with real-time polymerase chain reaction (PCR), we cultured monocyte-derived dendritic cells (mo-DCs) from carriers and used geneticin to assess the role of nonsense-mediated decay (NMD). We identified 3 additional carriers, demonstrating marked enrichment within our aHUS cohort. All carriers exhibited consistently reduced FI levels. Based on the mo-DC experiments, the variant creates a strong noncanonical splice site, leading to the predominant production of a splice variant with a 43-bp extension of exon 2, which generates a premature stop codon. Geneticin treatment increased the aberrant transcript level 4- to 7-fold, supporting its degradation via NMD. The CFI c.328+42G>A variant causes aberrant splicing and nearly complete loss of FI protein production. Besides causing FI deficiency in compound heterozygous form, this variant may contribute to the development of aHUS in heterozygotes. Our findings underscore the importance of analyzing intronic regions in complement-mediated diseases with unexplained genetic predisposition.